Improvement Of CAR-T Therapy with Gene Editing Technologies
DOI:
https://doi.org/10.54097/5gnk0h76Keywords:
CAR-T, Gene editing, CRISPR, TALENs.Abstract
In recent decades, after some breakthroughs in field of immunology, the numbers of studies related to cancer immunotherapy are exploding and growing. As a promising branch, adoptive cell therapy, has been shown to have a very high remission rate in patients with hematologic tumors as well as patients with metastatic and multi-therapy resistant melanoma by engineering T cell or natural killer (NK) cells outside the body. CAR-T therapy has gained significant recognition as a cancer treatment due to its exceptional effectiveness in treating hematologic malignancies. Consequently, there are researchers that wish to apply this technology to solid tumor therapy. But throughout this process, some solid tumor traits as well as the therapy's adverse effects constitute a significant challenge. With the advancement of gene editing technology, some researchers are able to alter the structure of CAR-T cells to increase the effectiveness of CAR-T treatment and address some drawbacks, such as the potential to cause GVHD and immunological rejection. Subsequent examples will illustrate this point broadly. By using TALENs to disrupt the TRAC gene or HLA-A locus of the MHC gene complex, the risk of GVHD and immunological rejection can be decreased. CRISPR/Cas9-mediated PD-1 protein knockout can extend the lifespan of CAR-T cells within the body. When toxicity manifests, appropriate staff may be able to eradicate every CAR-T cell in the patient's body by introducing a suicide gene or introducing a safety switch into CAR-T cells using CRISPR.
Downloads
References
[1] Dai, H., Wang, Y., Lu, X., & Han, W. (2016). Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy. Journal of the National Cancer Institute, 108(7), djv439. https://doi.org/10.1093/jnci/djv439 DOI: https://doi.org/10.1093/jnci/djv439
[2] Globerson Levin, A., Rivière, I., Eshhar, Z., & Sadelain, M. (2021). CAR T cells: Building on the CD19 paradigm. European journal of immunology, 51(9), 2151–2163. https://doi.org/10.1002/eji.202049064 DOI: https://doi.org/10.1002/eji.202049064
[3] Zhao, Z., Chen, Y., Francisco, N. M., Zhang, Y., & Wu, M. (2018). The application of CAR-T cell therapy in hematological malignancies: advantages and challenges. Acta Pharmaceutica Sinica B, 8(4), 539–551. https://doi.org/10.1016/j.apsb.2018.03.001 DOI: https://doi.org/10.1016/j.apsb.2018.03.001
[4] Zmievskaya, E., Valiullina, A., Ganeeva, I., Petukhov, A., Rizvanov, A., & Bulatov, E. (2021). Application of CAR-T Cell Therapy beyond Oncology: Autoimmune Diseases and Viral Infections. Biomedicines, 9(1), 59. https://doi.org/10.3390/biomedicines9010059 DOI: https://doi.org/10.3390/biomedicines9010059
[5] Razeghian, E., Nasution, M. K. M., Rahman, H. S., Gardanova, Z. R., Abdelbasset, W. K., Aravindhan, S., Bokov, D. O., Suksatan, W., Nakhaei, P., Shariatzadeh, S., Marofi, F., Yazdanifar, M., Shamlou, S., Motavalli, R., & Khiavi, F. M. (2021). A deep insight into CRISPR/Cas9 application in CAR-T cell-based tumor immunotherapies. Stem Cell Research & Therapy, 12(1). https://doi.org/10.1186/s13287-021-02510-7 DOI: https://doi.org/10.1186/s13287-021-02510-7
[6] Madison Blair B.,Patil Deepak,Richter Maximilian,Li Xianghong,Tong Min,Cranert Stacey... & Ostertag Eric M..(2022).Cas-CLOVER is a novel high-fidelity nuclease for safe and robust generation of TSCM-enriched allogeneic CAR-T cells.Molecular Therapy - Nucleic Acids329-. DOI: https://doi.org/10.1016/j.omtn.2022.07.021
[7] Khan, A., & Sarkar, E. (2022). CRISPR/Cas9 encouraged CAR-T cell immunotherapy reporting efficient and safe clinical results towards cancer. Cancer Treatment and Research Communications, 33, 100641. https://doi.org/10.1016/j.ctarc.2022.100641 DOI: https://doi.org/10.1016/j.ctarc.2022.100641
[8] Manghwar, H., Li, B., Ding, X., Hussain, A., Lindsey, K., Zhang, X., & Jin, S. (2020). CRISPR/Cas Systems in Genome Editing: Methodologies and Tools for sgRNA Design, Off‐Target Evaluation, and Strategies to Mitigate Off‐Target Effects. Advanced Science, 7(6). https://doi.org/10.1002/advs.201902312 DOI: https://doi.org/10.1002/advs.201902312
[9] Sadeqi Nezhad M, Yazdanifar M, Abdollahpour-Alitappeh M, Sattari A, Seifalian A, Bagheri N. Strengthening the CAR-T cell therapeutic application using CRISPR/Cas9 technology. Biotechnol Bioeng. 2021 Oct;118(10):3691-3705. doi: 10.1002/bit.27882. Epub 2021 Jul 21. PMID: 34241908. DOI: https://doi.org/10.1002/bit.27882
[10] Pacesa, M., Lin, C. H., Cléry, A., Saha, A., Arantes, P. R., Bargsten, K., Irby, M. J., Allain, F. H. T., Palermo, G., Cameron, P., Donohoue, P. D., & Jinek, M. (2022). Structural basis for Cas9 off-target activity. Cell, 185(22), 4067-4081.e21. https://doi.org/10.1016/j.cell.2022.09.026 DOI: https://doi.org/10.1016/j.cell.2022.09.026
[11] Lonez, C., & Breman, E. (2024). Allogeneic CAR-T Therapy Technologies: Has the Promise Been Met?. Cells, 13(2), 146. https://doi.org/10.3390/cells13020146 DOI: https://doi.org/10.3390/cells13020146
[12] Boch, Jens, et al. "Breaking the code of DNA binding specificity of TAL-type III effectors." Science 326.5959 (2009): 1509-1512. DOI: https://doi.org/10.1126/science.1178811
[13] Kevin J. Curran, Craig S. Sauter, Nancy A. Kernan, Susan E Prockop, Farid Boulad, Miguel Perales, Sergio A. Giralt, Isabelle Riviere, Xiuyan Wang, Jaap-Jan Boelens, Michel Sadelain, Renier Brentjens, Richard J. O'Reilly,Durable Remission Following “Off-the-Shelf” Chimeric Antigen Receptor (CAR) T-Cells in Patients with Relapse/Refractory (R/R) B-Cell Malignancies,Biology of Blood and Marrow Transplantation,Volume 26, Issue 3, Supplement,2020,Page S89,ISSN 1083-8791. DOI: https://doi.org/10.1016/j.bbmt.2019.12.590
[14] Benjamin R, Jain N, Maus MV, Boissel N, Graham C, Jozwik A, Yallop D, Konopleva M, Frigault MJ, Teshima T, Kato K, Boucaud F, Balandraud S, Gianella-Borradori A, Binlich F, Marchiq I, Dupouy S, Almena-Carrasco M, Pannaux M, Fouliard S, Brissot E, Mohty M; CALM Study Group. UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial. Lancet Haematol. 2022 Nov;9(11):e833-e843. doi: 10.1016/S2352-3026(22)00245-9. Epub 2022 Oct 10. PMID: 36228643. DOI: https://doi.org/10.1016/S2352-3026(22)00245-9
[15] Reyon D, Tsai SQ, Khayter C, Foden JA, Sander JD, Joung JK. FLASH assembly of TALENs for high-throughput genome editing. Nat Biotechnol. 2012 May;30(5):460-5. doi: 10.1038/nbt.2170. PMID: 22484455; PMCID: PMC3558947. DOI: https://doi.org/10.1038/nbt.2170
[16] Zhang S, Chen H, Wang J. Generate TALE/TALEN as Easily and Rapidly as Generating CRISPR. Mol Ther Methods Clin Dev. 2019 Feb 19;13:310-320. doi: 10.1016/j.omtm.2019.02.004. PMID: 30923728; PMCID: PMC6423989. DOI: https://doi.org/10.1016/j.omtm.2019.02.004
[17] Laurent Poirot, Brian Philip, Cécile Schiffer-Mannioui, Diane Le Clerre, Isabelle Chion-Sotinel, Sophie Derniame, Pierrick Potrel, Cécile Bas, Laetitia Lemaire, Roman Galetto, Céline Lebuhotel, Justin Eyquem, Gordon Weng-Kit Cheung, Aymeric Duclert, Agnès Gouble, Sylvain Arnould, Karl Peggs, Martin Pule, Andrew M. Scharenberg, Julianne Smith; Multiplex Genome-Edited T-cell Manufacturing Platform for “Off-the-Shelf” Adoptive T-cell Immunotherapies. Cancer Res 15 September 2015; 75 (18): 3853–3864. DOI: https://doi.org/10.1158/0008-5472.CAN-14-3321
[18] Ebrahimi, S., Khosravi, M. A., Raz, A., Karimipoor, M., & Parvizi, P. (2023). CRISPR-Cas Technology as a Revolutionary Genome Editing tool: Mechanisms and Biomedical Applications. PubMed, 27(5), 219–246. https://doi.org/10.61186/ibj.27.5.219 DOI: https://doi.org/10.61186/ibj.27.5.219
[19] Jiang, F., & Doudna, J. A. (2017). CRISPR–Cas9 Structures and Mechanisms. Annual Review of Biophysics, 46(1), 505–529. https://doi.org/10.1146/annurev-biophys-062215-010822 DOI: https://doi.org/10.1146/annurev-biophys-062215-010822
[20] Dimitri, A., Herbst, F., & Fraietta, J. A. (2022). Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing. Molecular Cancer, 21(1). https://doi.org/10.1186/s12943-022-01559-z DOI: https://doi.org/10.1186/s12943-022-01559-z
[21] Shimabukuro-Vornhagen, A., Gödel, P., Subklewe, M., Stemmler, H. J., Schlößer, H. A., Schlaak, M., Kochanek, M., Böll, B., & Von Bergwelt-Baildon, M. S. (2018). Cytokine release syndrome. Journal for ImmunoTherapy of Cancer, 6(1). https://doi.org/10.1186/s40425-018-0343-9 DOI: https://doi.org/10.1186/s40425-018-0343-9
[22] Brudno, J. N., & Kochenderfer, J. N. (2019). Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management. Blood Reviews, 34, 45–55. https://doi.org/10.1016/j.blre.2018.11.002 DOI: https://doi.org/10.1016/j.blre.2018.11.002
[23] Perales, M. A., Kebriaei, P., Kean, L. S., & Sadelain, M. (2018). Building a Safer and Faster CAR: Seatbelts, Airbags, and CRISPR. Biology of Blood and Marrow Transplantation, 24(1), 27–31. https://doi.org/10.1016/j.bbmt.2017.10.017 DOI: https://doi.org/10.1016/j.bbmt.2017.10.017
[24] Acharya, U. H., Dhawale, T., Yun, S., Jacobson, C. A., Chavez, J. C., Ramos, J. D., Appelbaum, J., & Maloney, D. G. (2019). Management of cytokine release syndrome and neurotoxicity in chimeric antigen receptor (CAR) T cell therapy. Expert Review of Hematology, 12(3), 195–205. https://doi.org/10.1080/17474086.2019.1585238 DOI: https://doi.org/10.1080/17474086.2019.1585238
[25] Tripathi, L., Ntui, V. O., Tripathi, J. N., Norman, D., & Crawford, J. (2023). A new and novel high‐fidelity genome editing tool for banana using Cas‐CLOVER. Plant Biotechnology Journal, 21(9), 1731–1733. https://doi.org/10.1111/pbi.14100 DOI: https://doi.org/10.1111/pbi.14100
Downloads
Published
Issue
Section
License
Copyright (c) 2024 Highlights in Science, Engineering and Technology
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
